3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
3
Thoracic
2
Gynecologic
2
Gastrointestinal
2
Plasma cell
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Esophageal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
fludarabine
3
Cyclophosphamide
3
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
zimberelimab
1
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
temsirolimus
1
sapanisertib
1
resiquimod
1
relatlimab
1
poly ICLC
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
marizomib
1
larotrectinib
1
ipatasertib
1
interferon-alfa-1b
1
erdafitinib
1
defactinib
1
dabrafenib
1
copanlisib
1
cobimetinib
1
cc-486
1
capivasertib
1
binimetinib
1
adavosertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
zimberelimab
×
Plasma cell
×
Clear all
NCT04772989
2025-08-28
ARC-12
Arcus Biosciences, Inc.
Phase 1
Completed
94 enrolled